Drug Discovery and Development Platform (DDD)

National platform

Share with others:

The SciLifeLab Drug Discovery and Development platform offers integrated drug discovery efforts to the Swedish academic research community. We offer industry standard infrastructure, expertise, and strategic support to help progress projects towards a pre-clinical proof-of-concept. The drug leads can be either a small molecule drug or a human antibody therapeutic. Services are offered in the following areas:

Up to 80 hour free support to prepare your project as a drug discovery project, including an initial drug target product profile, and a lead generation/antibody selection strategy with progression plans

In collaboration with Unit for Toxicology Sciences at Karolinska Institutet (Swetox Södertälje), projects are evaluated for target safety concerns and approved projects are offered chemical toxicity support (small molecules), immunotoxicity support (antibodies and small molecules) and safety support in the design of pharmacology in vivo studies. For more details contact Björn Glinghammar, Bjorn.Glinghammar@ki.se

Biochemical and cellular screening, both at single concentration in large compound libraries and to generate dose response data for iterative chemistry

Medicinal synthetic and computational chemistry

Analysis of drug metabolism and pharmacokinetics data for compounds and antibodies

Advanced analysis of in vitro pharmacology and systems pharmacology of compounds and antibodies

Biophysical characterization of molecular interaction between target and compounds or antibody

Importantly, the researcher/customer retains all rights and ownership during this process.

We encourage all academic researchers with an interest in turning their discoveries into cures for patients to contact us. For more information for how to start a project, please contact us via dddprojectproposal@scilifelab.se

SciLifeLab has been created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University.